LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

Home・Aktien・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Open

BrancheGesundheitswesen

36.57 -0.3

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.31

Max

36.96

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5M -128M
Verkäufe	6.8M 11M
EPS	-1.23
Gewinnspanne	-1,191.029
Angestellte	594
EBITDA	-18M -139M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+133.7% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-691M 3.7B
Vorheriger Eröffnungskurs	36.87
Vorheriger Schlusskurs	36.57

Nachrichtenstimmung

By Acuity

50%

159 / 345 Ranking in Healthcare

Crinetics Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Crinetics Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

133.7% Vorteil

12-Monats-Prognose

Durchschnitt 86 USD 133.7%

Hoch 97 USD

Tief 67 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Crinetics Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Crinetics Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

159 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.